Impact of Reimbursement for Biomarker Testing on Clinical Practice

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”

Related Videos

July 25, 2018

The Best Molecular Biomarkers Available for Informing Immunotherapy of Cancer

Dr David Spigel talks about currently available and emerging biomarkers that predict the greatest sensitivity to immunotherapy, including his insight into PD-L1, MSI, and TMB.

March 31, 2015

Integrating Cost into Treatment

According to Alexander Bastian, it’s very difficult to determine how to integrate cost into the equation of cancer care. He explains that cost should be considered early on and uses Dr. Zafar’s term of financial toxicity, meaning the burden of cost can be as bad or worse than a physical [ Read More ]